Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Expected to Post Earnings of -$0.30 Per Share

Wall Street analysts predict that Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) will post earnings of ($0.30) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Neoleukin Therapeutics’ earnings. The highest EPS estimate is ($0.28) and the lowest is ($0.33). Neoleukin Therapeutics reported earnings of ($0.24) per share in the same quarter last year, which would indicate a negative year over year growth rate of 25%. The firm is scheduled to report its next quarterly earnings results on Thursday, March 24th.

On average, analysts expect that Neoleukin Therapeutics will report full-year earnings of ($1.12) per share for the current fiscal year, with EPS estimates ranging from ($1.15) to ($1.10). For the next financial year, analysts forecast that the company will post earnings of ($1.39) per share, with EPS estimates ranging from ($1.79) to ($1.20). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that cover Neoleukin Therapeutics.

Neoleukin Therapeutics (NASDAQ:NLTX) last announced its earnings results on Thursday, November 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.28).

NLTX has been the subject of several recent analyst reports. Zacks Investment Research lowered Neoleukin Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 12th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Neoleukin Therapeutics in a research report on Monday, August 9th.

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Neoleukin Therapeutics by 5.0% in the second quarter. Vanguard Group Inc. now owns 1,593,582 shares of the company’s stock valued at $14,709,000 after purchasing an additional 75,179 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Neoleukin Therapeutics by 52.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 30,594 shares of the company’s stock valued at $377,000 after acquiring an additional 10,518 shares during the period. JPMorgan Chase & Co. increased its stake in Neoleukin Therapeutics by 33.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 16,267 shares of the company’s stock worth $151,000 after buying an additional 4,122 shares during the period. Goldman Sachs Group Inc. increased its stake in Neoleukin Therapeutics by 1,091.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 338,530 shares of the company’s stock worth $4,167,000 after buying an additional 310,107 shares during the period. Finally, Ameriprise Financial Inc. bought a new stake in shares of Neoleukin Therapeutics in the 1st quarter worth about $175,000. 63.42% of the stock is owned by institutional investors.

NLTX stock traded down $0.03 during midday trading on Friday, reaching $5.29. The stock had a trading volume of 192,020 shares, compared to its average volume of 207,759. The firm has a fifty day simple moving average of $6.90 and a two-hundred day simple moving average of $8.10. The stock has a market cap of $224.44 million, a PE ratio of -4.99 and a beta of 0.95. Neoleukin Therapeutics has a 52-week low of $4.66 and a 52-week high of $17.95.

Neoleukin Therapeutics Company Profile

Neoleukin Therapeutics, Inc operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.

Featured Article: 52 Week Highs and Lows

Get a free copy of the Zacks research report on Neoleukin Therapeutics (NLTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neoleukin Therapeutics (NASDAQ:NLTX)

Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.